IntroductionPharmacostatistical models can quantify different relationships and improve decision making in personalized medicine and drug development. Our objectives were to develop models describing non–small-cell lung cancer (NSCLC) dynamics during first-line treatment with erlotinib, and survival of the cohort.MethodsData from patients with advanced NSCLC (n = 39) treated first-line with erlotinib (150 mg/day) were analyzed using nonlinear mixed effects modeling. Exposure-driven disease-drug models were built to describe tumor metabolic and proliferative dynamics evaluated by positron emission tomography (PET) using 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F]fluoro-3′-deoxy-L-thymidine (FLT), respectively, at baseline, weeks 1 a...
Background: [18F]fluorodeoxyglucose (FDG)-PET is being evaluated as a tool for the early detection o...
Purpose: The aim of this prospective study was to evaluate whether [18F]FDG-PET/CT, performed within...
PURPOSE: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-PET/CT, performed within...
IntroductionPharmacostatistical models can quantify different relationships and improve decision mak...
Erlotinib improves progression-free survival (PFS) in metastatic non-small-cell lung cancer (mNSCLC)...
The purpose of this study was to evaluate the relevance for the prediction of clinical benefit of fi...
Aim: Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth f...
Purpose: The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion prolifera...
Background: The efficacy of erlotinib is controversial in patients with unknown EGFR mutational stat...
Erlotinib is an oral first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibi...
Purpose: Assessing clinical activity of molecularly targeted anticancer agents, especially in the ab...
F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response de...
Background: We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung...
<div><p>3′-deoxy-3′-[<sup>18</sup>F]fluoro-L-thymidine (FLT) and 2′-deoxy-2′-[<sup>18</sup>F]fluoro-...
Introduction:Erlotinib improves survival in patients with advanced non-small cell lung cancer who ha...
Background: [18F]fluorodeoxyglucose (FDG)-PET is being evaluated as a tool for the early detection o...
Purpose: The aim of this prospective study was to evaluate whether [18F]FDG-PET/CT, performed within...
PURPOSE: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-PET/CT, performed within...
IntroductionPharmacostatistical models can quantify different relationships and improve decision mak...
Erlotinib improves progression-free survival (PFS) in metastatic non-small-cell lung cancer (mNSCLC)...
The purpose of this study was to evaluate the relevance for the prediction of clinical benefit of fi...
Aim: Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth f...
Purpose: The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion prolifera...
Background: The efficacy of erlotinib is controversial in patients with unknown EGFR mutational stat...
Erlotinib is an oral first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibi...
Purpose: Assessing clinical activity of molecularly targeted anticancer agents, especially in the ab...
F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response de...
Background: We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung...
<div><p>3′-deoxy-3′-[<sup>18</sup>F]fluoro-L-thymidine (FLT) and 2′-deoxy-2′-[<sup>18</sup>F]fluoro-...
Introduction:Erlotinib improves survival in patients with advanced non-small cell lung cancer who ha...
Background: [18F]fluorodeoxyglucose (FDG)-PET is being evaluated as a tool for the early detection o...
Purpose: The aim of this prospective study was to evaluate whether [18F]FDG-PET/CT, performed within...
PURPOSE: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-PET/CT, performed within...